leisure time -WSS

leisure time

author：explore 2025-09-06 01:23:31 - browse：31

Adam's take main illustration — Molly Ferguson/STAT

Cytokinetics was founded 26 years ago but has not yet developed a drug successfully to approval. That makes Tuesday’s Food and Drug Administration decision on its treatment for heart failure a big deal — except nearly everyone, even investors who own Cytokinetics — hopes the agency rules against it.

Hoping the FDA rejects the Cytokinetics drug, called omecamtiv mecarbil, is a relatively uncommon, up-is-down, down-is-up situation, but it makes sense in this case because the business and science of the drug are not aligned.

Consider: Cytokinetics shares rose in December when an outside group of experts convened by the FDA to examine omecamtiv’s benefits and risks recommended against the medicine’s approval. On Tuesday, the FDA is most likely to heed that advice and turn down the company’s marketing application.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： New weight loss drugs vying to be the next Wegovy or Mounjaro

WSS

How housing is health care on Long Island

Britain’s MI6 chief says his spies are using AI to disrupt flow of weapons to Russia

New Covid vaccine is recommended for everyone 6 months or older

Generate Biomedicines machine learning biotech raises $273M

FDA seeking to stop procedures at two unregulated stem cell clinics

Long Covid needs a new name — and a new frame

leisure time

leisure time

leisure time

Medicare details structure of new drug price negotiation program

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Psychedelics group wrestles with new pharma identity

Manchin plays down potential 3rd

United colonoscopy coverage change 'may cost lives,' doctors say

Regeneron agrees to White House price limits on anti

Sports medicine is finally prioritizing gender equality

FDA proposes changes to key medical devices approval pathway

Walensky prepares to leave CDC — and Congress — behind

ER docs worry over extreme heat as a 'mass casualty event'

focus

Telehealth for opioid use disorder is lifesaving

Food makers to regulators: Ultra

Generate Biomedicines machine learning biotech raises $273M

FDA proposes changes to key medical devices approval pathway

IRA could hurt research into orphan drugs for rare diseases

ER docs worry over extreme heat as a 'mass casualty event'

focus

leisure time

explore

leisure time